Departing Leo Pharma executive plans to follow Genmab's example for new biotech: "It's a major aspiration, but it's can be done"

Leo Pharma's departing head of R&D wants to create a pharmaceutical venture in his new position as the CEO of Union Therapeutics – inspired by Jan van de Winkel and Genmab.

Future Union Therapeutics CEO Kim Kjøller. Photo: Leo Pharma / PR

Kim Kjøller's decision to leave the role of Executive Vice President Global Research&Development at Leo Pharma in favor of a CEO position in a minor biotech firm partly owes to his vision of creating a new frontrunner in the Danish pharmaceutical industry.

Kjøller tells MedWatch this in the wake of Tuesday's announcement that he is leaving Leo Pharma to become the CEO of the biotech company Union Therapeutics.

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

Related articles